Naima Ghailani Nourouti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Naima Ghailani Nourouti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Mohcine Bennani Mechita
Intelligent Automation and BioMed Genomics Laboratory, Biology Department, Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaadi University-Tetouan, Tangier 90000, Morocco
3 shared publications - Amina Barakat
Biology Department, Faculty of Sciences and Technology of Tangier, Abdelmalek Essaâdi University, Tetouan, Morocco
2 shared publications - Abdelilah Laraqui
Mohammed V University
1 shared publication - Achraf Laghmich
Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaâdi, Tangier 90000, Morocco
1 shared publication Amina Barakat
Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, University Abdelmalek Essaadi, Tangier, Morocco
1 shared publication- Assia Bouhoudan
Abdelmalek Essaadi University
1 shared publication
Latest Publications
- Open Access
- 24 March 2025
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 9 (2) , 17
The role of gut microbiome in obesity and metabolic dysfunctions: Insights and therapeutic potential
Obesity is a chronic inflammatory disease defined by an excessive accumulation of body fat. The human gut microbiota (GM) is an intricate ecosystem of microorganisms living symbiotically within the gastrointestinal tract and has emerged as a key player in health and metabolic diseases. Recently, several studies have increasingly revolved around understanding the specific compositions and strains of GM and their potential impact on obesity. This review provides a summary of the most recent findings regarding obesity and newly developed therapies that show exceptional efficacy in treating this condition. In addition, it explores different GM strains that may contribute to the progression and development of obesity. This article summarizes the molecular insights involved in the relationship between obesity and GM, the characteristics of this ecosystem, and its involvement in human metabolism, energy balance, and inflammation leading to obesity. Furthermore, it examines the bacteria most engaged in managing obesity. These findings contribute to a better understanding of this significant and intricate relationship, ultimately aiding in obesity prevention.
- 24 March 2025
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 9 (2) , 17
Open AccessThe role of gut microbiome in obesity and metabolic dysfunctions: Insights and therapeutic potential
Obesity is a chronic inflammatory disease defined by an excessive accumulation of body fat. The human gut microbiota (GM) is an intricate ecosystem of microorganisms living symbiotically within the gastrointestinal tract and has emerged as a key player in health and metabolic diseases. Recently, several studies have increasingly revolved around understanding the specific compositions and strains of GM and their potential impact on obesity. This review provides a summary of the most recent findings regarding obesity and newly developed therapies that show exceptional efficacy in treating this condition. In addition, it explores different GM strains that may contribute to the progression and development of obesity. This article summarizes the molecular insights involved in the relationship between obesity and GM, the characteristics of this ecosystem, and its involvement in human metabolism, energy balance, and inflammation leading to obesity. Furthermore, it examines the bacteria most engaged in managing obesity. These findings contribute to a better understanding of this significant and intricate relationship, ultimately aiding in obesity prevention.
- Open Access
- 19 December 2024
- Published by Springer Nature in Discover Food
- Vol. 4 (1) , 1-15
Moroccan eating habits during COVID-19 lockdown: a preliminary analysis
- 19 December 2024
- Published by Springer Nature in Discover Food
- Vol. 4 (1) , 1-15
Open AccessMoroccan eating habits during COVID-19 lockdown: a preliminary analysis
- 3 May 2020
- Published by Taylor & Francis in Hemoglobin
- Vol. 44 (3) , 190-194
XmnI Polymorphism in Sickle Cell Disease in North Morocco
Sickle cell disease is one of the most common severe monogenic disorders in the world. The –158 XmnI polymorphism (C>T) of the Gγ-globin gene promoter is known to be associated with increased expression of the Gγ-globin gene, thus, higher production of Hb F and lesser clinical severity. This study aims to determine the frequency of the XmnI polymorphism and its association with Hb F levels as a modulating factor of sickle cell disease severity in north Moroccan patients. Three hundred and eight subjects carrying the sickle cell mutation and 160 healthy individuals were recruited at the regional hospital of Larache, Morocco. The complete blood count and the Hb F levels were analyzed. The XmnI polymorphism was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique and statistical analysis were done using the Statistical Package for Social Sciences software version 20. Our results estimated the allelic frequency of the XmnI polymorphism in our population at 15.8%. Out of 468 samples, 7.6% were homozygous [+/+] and 16.4% were heterozygous [+/−] for the XmnI polymorphism. This polymorphism was revealed at 20.6% in SS patients, 24.2% in AS carriers, 28.6% in Hb S (HBB: c.20A>T)/β-thalassemia (β-thal) patients and 22.5% in AA subjects. The north Moroccan sickle cell disease patients have shown a low frequency of the XmnI polymorphism. This was later found to be associated with high Hb F levels and mild clinical severity.
- 3 May 2020
- Published by Taylor & Francis in Hemoglobin
- Vol. 44 (3) , 190-194
XmnI Polymorphism in Sickle Cell Disease in North Morocco
Sickle cell disease is one of the most common severe monogenic disorders in the world. The –158 XmnI polymorphism (C>T) of the Gγ-globin gene promoter is known to be associated with increased expression of the Gγ-globin gene, thus, higher production of Hb F and lesser clinical severity. This study aims to determine the frequency of the XmnI polymorphism and its association with Hb F levels as a modulating factor of sickle cell disease severity in north Moroccan patients. Three hundred and eight subjects carrying the sickle cell mutation and 160 healthy individuals were recruited at the regional hospital of Larache, Morocco. The complete blood count and the Hb F levels were analyzed. The XmnI polymorphism was determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique and statistical analysis were done using the Statistical Package for Social Sciences software version 20. Our results estimated the allelic frequency of the XmnI polymorphism in our population at 15.8%. Out of 468 samples, 7.6% were homozygous [+/+] and 16.4% were heterozygous [+/−] for the XmnI polymorphism. This polymorphism was revealed at 20.6% in SS patients, 24.2% in AS carriers, 28.6% in Hb S (HBB: c.20A>T)/β-thalassemia (β-thal) patients and 22.5% in AA subjects. The north Moroccan sickle cell disease patients have shown a low frequency of the XmnI polymorphism. This was later found to be associated with high Hb F levels and mild clinical severity.